Clinical trial
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell…
NCT00244764 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00244764 |
|---|---|
| Title | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma |
| Official title | A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | GW786034, Placebo |
| Enrollment | 225 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Sep 1, 2013 |
| First posted | Oct 27, 2005 |
| Last update posted | Mar 27, 2017 |
| Countries | Australia, Belgium, China, Czechia, Hong Kong, Israel, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: